http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Merus N.V. (MRUS) Reports MCLA-145 Clinical Data
-
Merus Presents Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021
-
Merus Presents Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021
-
Merus Announces Poster Presentation on Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021
-
Merus Announces Poster Presentation on Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021
-
Merus to Participate in a Fireside Chat at the Jefferies London Healthcare Conference (Virtual)
-
Merus to Participate in a Fireside Chat at the Jefferies London Healthcare Conference (Virtual)
-
Merus N.V. (MRUS) Provides Regulatory Update on Zenocutuzumab; Reports Earnings
-
Merus Announces Regulatory Update on Zenocutuzumab, Financial Results for the Third Quarter and Provides Business Update
-
Merus Announces Regulatory Update on Zenocutuzumab, Financial Results for the Third Quarter and Provides Business Update
-
Merus Presents Early Clinical Data on MCLA-158 and Preclinical Data on Zenocutuzumab at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
-
Merus Presents Early Clinical Data on MCLA-158 and Preclinical Data on Zenocutuzumab at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
-
Merus Announces Poster Presentations on Zenocutuzumab and MCLA-158 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
-
Merus Announces Poster Presentations on Zenocutuzumab and MCLA-158 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
-
Merus to Participate in Upcoming Investor Conferences
-
Merus to Participate in Upcoming Investor Conferences
-
Merus Announces Financial Results for the Second Quarter and Provides Business Update
-
Merus Announces Financial Results for the Second Quarter and Provides Business Update
-
Merus N.V. (MRUS) Announces Publication in Nature Communications on MCLA-145’s Novel Mechanism of Action Promoting Tumor Immunity and Context Dependent T-Cell Costimulation
-
Merus Announces Publication in Nature Communications on MCLA-145’s Novel Mechanism of Action Promoting Tumor Immunity and Context Dependent T-Cell Costimulation
-
Merus Announces Publication in Nature Communications on MCLA-145’s Novel Mechanism of Action Promoting Tumor Immunity and Context Dependent T-Cell Costimulation
-
Merus to Participate in William Blair's Biotech Focus Conference 2021
-
Merus to Participate in William Blair's Biotech Focus Conference 2021
-
Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting (Oral Abstract)
-
Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting (Oral Abstract)
-
Merus to Participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference
-
Merus to Participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference
-
Merus Announces Publication of Abstract on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
-
Merus Announces Publication of Abstract on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
-
Merus Announces Collaborations in Israel, Italy and Spain to Increase Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the Phase 1/2 eNRGy Clinical Tri
-
Merus Announces Collaborations in Israel, Italy and Spain to Increase Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the Phase 1/2 eNRGy Clinical Tri
-
Merus to Participate in a Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference
-
Merus to Participate in a Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference
-
Merus Announces Financial Results for the First Quarter and Provides Business Update
-
Merus Announces Financial Results for the First Quarter and Provides Business Update
-
UPDATE: Merus N.V. (MRUS) Reports First Patient Treated in Phase 1/2 Clinical Trial of MCLA-129 in Advanced Lung Cancer and Other Solid Tumors
-
Merus Announces First Patient Treated in Phase 1/2 Clinical Trial of MCLA-129 in Advanced Lung Cancer and Other Solid Tumors
-
Merus Announces First Patient Treated in Phase 1/2 Clinical Trial of MCLA-129 in Advanced Lung Cancer and Other Solid Tumors
-
Zenocutuzumab Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology Annual Meeting
-
Zenocutuzumab Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology Annual Meeting
-
Merus Announces Financial Results for the Fourth Quarter and Full Year 2020 and Provides Business Update
-
Merus Announces Financial Results for the Fourth Quarter and Full Year 2020 and Provides Business Update
-
Merus Announces Poster Presentations for Zenocutuzumab and MCLA-129 at the American Association for Cancer Research 2021 Annual Meeting
-
Merus Announces Poster Presentations for Zenocutuzumab and MCLA-129 at the American Association for Cancer Research 2021 Annual Meeting
-
Merus to Participate in a Fireside Chat at the 33rd Annual Roth Conference
-
Merus to Participate in a Fireside Chat at the 33rd Annual Roth Conference
-
Merus to Participate in Upcoming Investor Conferences
-
Merus to Participate in Upcoming Investor Conferences
-
Lilly (LLY) and Merus NV (MRUS) Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
-
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
